The Chemours Company (NYSE:CC) Receives $17.22 Average PT from Brokerages

Shares of The Chemours Company (NYSE:CC - Get Free Report) have received a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the stock, Marketbeat reports. Four analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $17.22.

Several equities research analysts recently issued reports on CC shares. UBS Group dropped their price target on Chemours from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Royal Bank Of Canada dropped their target price on shares of Chemours from $17.00 to $14.00 and set an "outperform" rating on the stock in a report on Thursday, May 8th. Wall Street Zen downgraded shares of Chemours from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. Barclays lowered their price objective on shares of Chemours from $16.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 28th. Finally, Morgan Stanley dropped their price objective on shares of Chemours from $22.00 to $15.00 and set an "equal weight" rating on the stock in a research note on Monday, May 12th.

Insiders Place Their Bets

In other Chemours news, CFO Shane Hostetter purchased 4,450 shares of Chemours stock in a transaction on Monday, May 19th. The stock was bought at an average price of $11.28 per share, for a total transaction of $50,196.00. Following the transaction, the chief financial officer now owns 59,694 shares of the company's stock, valued at $673,348.32. The trade was a 8.06% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Damian Gumpel purchased 13,400 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was acquired at an average cost of $9.22 per share, with a total value of $123,548.00. Following the purchase, the insider now owns 123,879 shares of the company's stock, valued at approximately $1,142,164.38. This represents a 12.13% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 25,672 shares of company stock worth $251,573. Insiders own 0.47% of the company's stock.

Hedge Funds Weigh In On Chemours

Large investors have recently bought and sold shares of the stock. FNY Investment Advisers LLC acquired a new stake in shares of Chemours in the 1st quarter worth approximately $27,000. UMB Bank n.a. lifted its position in Chemours by 73.9% in the first quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock worth $30,000 after purchasing an additional 948 shares during the period. Farther Finance Advisors LLC lifted its position in Chemours by 170.7% in the first quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company's stock worth $30,000 after purchasing an additional 1,444 shares during the period. SouthState Corp bought a new position in Chemours during the 1st quarter valued at $34,000. Finally, Quadrant Capital Group LLC boosted its stake in Chemours by 100.4% during the 4th quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company's stock valued at $38,000 after purchasing an additional 1,119 shares in the last quarter. Institutional investors and hedge funds own 76.26% of the company's stock.

Chemours Stock Up 2.6%

Shares of CC traded up $0.29 during midday trading on Friday, hitting $11.44. The company had a trading volume of 3,581,238 shares, compared to its average volume of 2,297,820. The stock has a market cap of $1.71 billion, a price-to-earnings ratio of 10.93 and a beta of 1.64. The company's 50 day moving average price is $11.21 and its 200 day moving average price is $14.48. The company has a quick ratio of 0.83, a current ratio of 1.75 and a debt-to-equity ratio of 7.01. Chemours has a 52 week low of $9.13 and a 52 week high of $25.54.

Chemours (NYSE:CC - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.06). Chemours had a net margin of 0.54% and a return on equity of 23.82%. The firm had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.36 billion. During the same period in the prior year, the firm earned $0.32 earnings per share. The firm's quarterly revenue was up .4% compared to the same quarter last year. On average, equities research analysts predict that Chemours will post 2.03 EPS for the current year.

Chemours Announces Dividend

The company also recently announced a dividend, which was paid on Monday, June 16th. Shareholders of record on Monday, May 19th were paid a dividend of $0.0875 per share. This represents a yield of 3.17%. The ex-dividend date was Friday, May 16th. Chemours's payout ratio is 175.00%.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.